Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Phase 3
Therapeutic Area: Oncology
Indication: Non-small-cell lung cancer
US FDA Fast Track Designation
HER2 is a member of the ErbB family of receptor tyrosine kinases. Mutations in HER2 can lead to overexpression and overactivation, which can in turn result in uncontrolled cell production, inhibition of cell death, and promotion of tumor growth and spread. HER2 gene alterations are seen across a number of different cancer types.
Zongertinib (BI 1810631) is an irreversible HER2-selective tyrosine kinase inhibitor (TKI) currently being investigated in a phase III clinical trial.